1214324-64-7

Basic information

• Product Name: Methyl 2-Fluoro-3-hydroxybenzoate
• Synonyms: Methyl 2-Fluoro-3-hydroxybenzoate;2-Fluoro-3-hydroxy-benzoic acid methyl ester
• CAS NO: 1214324-64-7
• Molecular Formula: C8H7FO3
• Molecular Weight: 170.1377832
• Mol File: 1214324-64-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-Fluoro-3-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-Fluoro-3-hydroxybenzoate(1214324-64-7)
• EPA Substance Registry System: Methyl 2-Fluoro-3-hydroxybenzoate(1214324-64-7)

Safety Data

• Hazardous Substances Data: 1214324-64-7(Hazardous Substances Data)

Usage

General Description

Methyl 2-Fluoro-3-hydroxybenzoate is a specific kind of methyl benzoate that is used in organic chemistry. It has a fluorine atom attached to the second carbon of its benzoate group and a hydroxyl group (-OH) on the third carbon. Its molecular formula is C8H7FO3. Please note that handling this chemical requires specialized knowledge as it may have a variety of potential risks and it is advised to be used only in controlled laboratory conditions by trained professionals. This chemical is often applied in the synthesis of other chemicals, pharmaceuticals, or compounds used in research. More detailed information on its properties and applications can be found in relevant chemical databases and literature.

Upstream product

• 67-56-1 methanol 
• 91658-92-3 2-fluoro-3-hydroxybenzoic acid 

Relevant articles and documents

Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics

In the present study, a series of benzamides, endowed with potent dopamine D2, serotonin 5-HT1A and 5-HT2A receptors properties, was synthesized and evaluated as potential antipsychotics. Among them, 3-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-N-methylbenzamide (21) and its fluoro-substituted analogue (22) held the best pharmacological binding profiles. They not only presented potent activities for D2, 5-HT1A, and 5-HT2A receptors, but were also endowed with low activities for 5-HT2C, H1 receptors and hERG channels, suggesting a low propensity of inducing weight gain and QT prolongation. In animal models, compounds 21 and 22 reduced phencyclidine-induced hyperactivity with a high threshold for catalepsy induction. It thus provides potential candidates for further preclinical studies.